SYMBIOTEC
Symbiotec Pharmalab Limited Q2 & H1fy27: Strong Business Momentum and Growth
Symbiotec Pharmalab Limited (SYMBIOTEC) reports strong Q2 & H1FY27 performance with 11% Y-o-Y API revenue growth and key business updates.
Symbiotec Pharmalab Limited (SYMBIOTEC) showcased robust Q2 & H1FY27 performance, reflecting strong business momentum across its core and emerging growth segments. The company’s API business delivered steady revenue growth of 11% year-on-year in H1FY27, driven by healthy volume growth and a favorable product mix. This solid performance provides a strong foundation as the company pursues new opportunities and expands into adjacent growth segments.
API Business Updates
The API business continues to thrive, with successful completion of four major regulatory audits, including EUGMP and USFDA audits for both Rau and Pithampur plants. Additionally, the company signed a licensing agreement for the distribution of two DCV products in the US, with part of the revenue recognized in Q2 FY27 and the rest expected in upcoming quarters. Commercial supplies are anticipated to commence next year, further boosting revenue and profitability.
Emerging Growth Engines
Symbiotec Pharmalab Limited is also making significant strides in its emerging growth segments. The company is in advanced stages of finalizing a 10-year take-or-pay agreement with a Europe-based company in the alternative protein space, which will enable the expansion of its bio-manufacturing capacity in a phased manner. Moreover, the company has filed its first molecule ANDA for DCV successfully and is scheduled to file the second ANDA in Q4 FY27. These initiatives underscore the company’s commitment to investing in further product development and regulatory filings to strengthen its presence in the complex injectables space.
Looking ahead, Symbiotec Pharmalab Limited remains confident in its growth outlook and the potential of its emerging businesses. The company believes its Injectables and CDMO businesses have the potential to scale meaningfully over the coming years and ultimately reach a size comparable to its established API business.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited. Here’s a quick read on where the business and the stock stand today.
Symbol SYMBIOTEC not found in TradeAlone database.
SYMBIOTEC
Symbiotec Pharmalab Limited (symbiotec) Q1fy27: Steady Performance with Revenue Up 6%
Symbiotec Pharmalab Limited (SYMBIOTEC) reports steady performance for Q1FY27 with revenue up 6% and EBITDA growth of 9%.
Symbiotec Pharmalab Limited (SYMBIOTEC) has delivered steady performance for Q1FY27, showcasing consistent growth in its core API business and promising developments in new growth areas. The company’s operating revenue for the API business increased by 6% year-on-year to Rs. 215.3 crore, driven by a favorable sales mix and robust demand.
API Business Growth
The API business, with its three decades of steroid chemistry depth and regulated market presence, saw an EBITDA growth of 9%, reaching Rs. 65.8 crore. The gross margins remained upwards of 60%, and EBITDA margins were steady at around 30%. This growth is expected to further accelerate in subsequent quarters as new capacities come online.
Consolidated Performance
Consolidated revenues for the quarter stood at Rs. 218.2 crore, up from Rs. 203.2 crore in the same period last year. Despite a drag from expenses related to new businesses not yet generating revenues, the company remains optimistic about revenue generation from these new ventures in the next 6-12 months. Consolidated EBITDA was Rs. 45.2 crore, down from Rs. 58.0 crore due to higher operating expenses.
Key Operational Highlights
Symbiotec Pharmalab Limited has made significant strides in its regulatory audits, successfully completing four major audits including EUGMP and USFDA audits. The company has also signed a licensing agreement for the distribution of two DCV products in the US and filed its first ANDA for a DCV product in September 2026. Additionally, the company has secured long-term agreements with customers for its biotech CDMO services, further solidifying its position in the market.
As Symbiotec Pharmalab Limited continues to invest in new revenue-generating businesses, the company expects to see a positive impact on its consolidated performance in the coming quarters. With a total gross capex of approximately Rs. 1,666 crore planned by the end of FY27, the company is well-positioned for sustained growth and innovation in the pharmaceutical and biotechnology sectors.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited. Here’s a quick read on where the business and the stock stand today.
Symbol SYMBIOTEC not found in TradeAlone database.
-
EFCIL3 days agoEfc (I) Limited Q2 FY27: Revenue Up 30%, PAT Rises 36%
-
GLAND2 days agoGland Pharma Limited (gland) Receives Approval for Methylprednisolone Acetate Injectable
-
POWERGRID2 days agoPower Grid Corporation of India Limited Q2 & H1 FY27 Earnings Update: Robust Performance and Growth
-
Auto Manufacturers2 days agoEicher Motors Limited Eichermot: Royal Enfield Unveils Exciting New Models at EICMA 2026
-
Banks - Regional2 days agoState Bank of India (sbin) Q2fy27 Results: Net Profit Up 14.28% Yoy
-
ANTHEM2 days agoAnthem Biosciences Limited (NSE: Anthem) Q2 & H1 FY27 Results: Robust Performance and Margin Expansion
-
Computer Hardware2 days agoGng Electronics Limited (NSE: Ebgng) Q2 & H1 FY27 Results: Revenue Up 42% Yoy, PAT Surges 72.5%
-
Industrials2 days agoInox India Limited (inoxcva) Q2 & H1 FY27 Results: Revenue Surges 26.6% Yoy, PAT Up 7.8%